Pill of Choice

This article appeared in the October 23, 2000 edition of The Nation.

October 5, 2000

It took twelve years for the FDA to approve mifepristone--also known as RU-486--and most of that time had less to do with medicine than with the politics of abortion. Still, the late-September decision was a tremendous victory for American women. In approving RU-486, the FDA showed that science and good sense can still carry the day, even in an election year.

The long delay may even backfire against the drug's opponents. In 1988, when mifepristone was legalized in France, it was a medical novelty as well as a political flashpoint. Today, it's been accepted in thirteen countries, including most of Western Europe; it's been taken by more than a half-million women and studied, it sometimes seems, by almost as many researchers. By the end of the approval process, the important medical professional organizations--the AMA, the American Medical Women's Association, the American College of Obstetricians and Gynecologists--had given mifepristone their blessing; impressive percentages of Ob-Gyns and family practitioners said they would consider prescribing it; thousands of US women had taken it in clinical trials and given it high marks, with 97 percent in one study saying they would recommend it to a friend. Against this background of information and experience, the antichoicers' attempt to raise fears about the drug's safety sounds desperate and insincere.

In a normal country, RU-486 would simply be another abortion method, its use a matter of personal preference (in France it's the choice of 20 percent of women who have abortions, while in Britain only 6 percent opt for it). But in the United States, where abortion clinics are besieged by fanatics and providers wear bulletproof vests, mifepristone's main significance lies in its potential to widen access to abortion, especially in those 86 percent of US counties that possess no abortion clinic, by making it private--doctors unable or unwilling to perform surgical abortions could prescribe it, and women could take it at home.

Subscriber Login

4 ISSUES FREE

Subscribe Now!

The only way to read this article and the full contents of each week's issue of The Nation online is by subscribing to the magazine. Subscribe now and read this article -- and every article published since for the past five years -- right now.

There's no obligation -- try The Nation for four weeks free.

.
Advertisement
Advertisement
Advertisement

Blogs

» Act Now!

Coal Country | "This is a civil war."
Peter Rothberg
Posted 18 minutes ago

» The Notion

A Blow to Privatization in Israel (and Perhaps Beyond) | A potentially historic ruling on prison privatization, in Israel.
Eyal Press
Posted at 9:48 ET

» The Dreyfuss Report

Can China Help on Afghanistan? | Beijing wants a broader role in the Middle East and South Asia. Will Obama bring them in?
Robert Dreyfuss
6 Comments
Posted at 8:50 ET

» Editor's Cut

Around the Nation | The week we went Rouge. Plus, Moyers on Afghanistan.
Katrina vanden Heuvel
56 Comments

» The Beat

Health Care Bill Advances, as Harry Reid Trumps Sarah Palin | The death panelist-in-chief rallied her followers to "KILL THE BILL." But 60 senators decided to follow the real leader.
John Nichols
67 Comments

» Altercation

Slacker Friday | The "Second Amendment" sale; the raving paranoids of the right.
Eric Alterman